Journal
PROSTATE
Volume 77, Issue 15, Pages 1489-1498Publisher
WILEY
DOI: 10.1002/pros.23425
Keywords
hyperactive mTOR; interferon regulatory factor 1; LNCaP; NED
Categories
Funding
- JSPS KAKENHI [25291042, 17H03802]
- Comprehensive Brain Science Network [221S0003]
- Grants-in-Aid for Scientific Research [17H03802, 25115010] Funding Source: KAKEN
Ask authors/readers for more resources
BackgroundNeuroendocrine-differentiated prostate cancer (NEPCa) is refractory to androgen deprivation therapy and shows a poor prognosis. The underlying mechanisms responsible for neuroendocrine differentiation (NED) are yet to be clarified. In this study, we investigated the role of mammalian target of rapamycin (mTOR) in NEPCa. MethodsWe utilized a gain-of-function analysis by establishing a human PCa LNCaP stable line that expresses hyperactive mTOR (LNCaP-mTOR). Then, we employed a comprehensive mass spectrometric analysis to identify a key transcription factor in LNCaP-mTOR, followed by a loss-of-function analysis using CRISPR/Cas system. ResultsThe activation of mTOR induced NED. We observed significant cell growth arrest in NED of LNCaP-mTOR, which accompanied increased expression of p21(WAF1/CIP1). A comprehensive mass spectrometric analysis identified interferon regulatory factor 1 (IRF1) as a key transcription factor in growth arrest of LNCaP-mTOR. The disruption of IRF1 gene in LNCaP-mTOR reversed cell growth arrest along with the suppression of its target p21(WAF1/CIP1). These results indicate that the growth arrest in NED is at least in part dependent on IRF1 through the induction of p21(WAF1/CIP1). ConclusionsWe identified active mTOR as a novel inducer of NED, and elucidated a mechanism underlying the malignant transformation of NEPCa by recapitulating NED in vitro.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available